Inhibit a Tumor-Relevant Interaction
A cyclic peptide can be developed to bind an extracellular receptor or disrupt a protein interface. Target selection begins with structural and functional evidence. The campaign then compares binding geometry, activity in relevant cells, selectivity and exposure. For an intracellular target, permeability and subcellular engagement become central selection criteria.
